KKKasper Aalbæk Kjærgaard

Kasper Aalbæk Kjærgaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kasper Aalbæk Kjærgaard has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of postoperative complications and type 2 diabetes on breast cancer recurrence and mortality

    by Kasper A Kjærgaard, Peer Christiansen, Signe Borgquist, Deirdre Cronin-Fenton

    Background: Type 2 diabetes (T2D) is associated with increased risk of complications after breast cancer surgery. This study investigated systemic and surgical-site postoperative complications and the risk of early and late breast cancer recurrence and mortality, overall, and according to T2D status. Methods: From the Danish Breast Cancer Group (DBCG) and Danish registries, a cohort of women with incident early-stage breast cancer diagnosed 1996–2017 was assembled. All women underwent mastectomy or breast-conserving surgery. Using diagnostic codes, systemic and surgical-site complications within 30 days of surgery were defined. Early recurrence (<10 years from diagnosis) was ascertained from the DBCG and late recurrence (≥10 years after diagnosis) via a validated registry-based algorithm. Incidence rates (IRs) per 1000 person-years were calculated, and Cox regression was used to estimate adjusted hazard ratios (aHRs) of early and late recurrence, and death, according to postoperative complications. Potential effect measure modification by T2D was evaluated. Results: Among 58 198 women undergoing breast cancer surgery, 6285 (10.8%) had postoperative complications. Overall, 747 and 5756 women with and without complications developed early recurrence (IR: 19.7 and 17.9, aHR = 1.04, 95% c.i. 0.96, 1.13), whereas 314 and 3314 women developed late recurrence (IR: 23.9 and 26.0, and aHR = 0.90, 95% c.i. 0.80, 1.02). Prevalent T2D did not impact these findings. Women with postoperative complications had higher mortality rates than those without complications (aHR = 1.11; 95% c.i. 1.06, 1.16); especially those with T2D versus no T2D (aHR = 1.50; 95% c.i. 1.30, 1.73). Conclusion: Postoperative complications after breast cancer primary surgery did not impact recurrence risk but had a negative impact on survival, especially in women with T2D.


  • Impact of postoperative complications and type 2 diabetes on breast cancer recurrence and mortality

    by Kasper A Kjærgaard, Peer Christiansen, Signe Borgquist, Deirdre Cronin-Fenton

    Background: Type 2 diabetes (T2D) is associated with increased risk of complications after breast cancer surgery. This study investigated systemic and surgical-site postoperative complications and the risk of early and late breast cancer recurrence and mortality, overall, and according to T2D status. Methods: From the Danish Breast Cancer Group (DBCG) and Danish registries, a cohort of women with incident early-stage breast cancer diagnosed 1996–2017 was assembled. All women underwent mastectomy or breast-conserving surgery. Using diagnostic codes, systemic and surgical-site complications within 30 days of surgery were defined. Early recurrence (<10 years from diagnosis) was ascertained from the DBCG and late recurrence (≥10 years after diagnosis) via a validated registry-based algorithm. Incidence rates (IRs) per 1000 person-years were calculated, and Cox regression was used to estimate adjusted hazard ratios (aHRs) of early and late recurrence, and death, according to postoperative complications. Potential effect measure modification by T2D was evaluated. Results: Among 58 198 women undergoing breast cancer surgery, 6285 (10.8%) had postoperative complications. Overall, 747 and 5756 women with and without complications developed early recurrence (IR: 19.7 and 17.9, aHR = 1.04, 95% c.i. 0.96, 1.13), whereas 314 and 3314 women developed late recurrence (IR: 23.9 and 26.0, and aHR = 0.90, 95% c.i. 0.80, 1.02). Prevalent T2D did not impact these findings. Women with postoperative complications had higher mortality rates than those without complications (aHR = 1.11; 95% c.i. 1.06, 1.16); especially those with T2D versus no T2D (aHR = 1.50; 95% c.i. 1.30, 1.73). Conclusion: Postoperative complications after breast cancer primary surgery did not impact recurrence risk but had a negative impact on survival, especially in women with T2D.

  • Open Access

    Risk of type 2 diabetes after breast cancer treatment: a population-based cohort study in Denmark

    by Kasper A Kjærgaard, Astrid Kousholt, Reimar W Thomsen, Kirsten M Woolpert, Henrik T Sørensen, Signe Borgquist, Deirdre Cronin-Fenton

    Data on type 2 diabetes (T2D) risk after breast cancer (BC) could guide preventive strategies. Yet, studies had limitations regarding sample size, follow-up, and contemporary treatments. We evaluated the risk of T2D after BC overall, by cancer treatment, and compared with a matched cohort of cancer-free women. We assembled a population-based cohort of early-stage BC patients aged ≥30 years diagnosed during 1996-2021 in Denmark. We created a comparison cohort of five cancer- and T2D-free women for each BC case, matched six months after BC diagnosis date on age and region. We followed both cohorts until T2D diagnosis, emigration, death, or December 31, 2022. We computed 5-year cumulative incidences and used Cox models to calculate time-varying adjusted hazard ratios (aHR) of T2D. Among 74,526 BC survivors and 372,630 matched cancer-free women, 5-year cumulative incidences of T2D were 3.8% (95%CI = 3.7-3.9) and 3.3% (95%CI = 3.3-3.4), respectively. The aHR of T2D was elevated but attenuated over follow-up (aHR5-years=1.20, 95%CI = 1.15-1.25, and aHR15-years=1.09, 95%CI = 1.05-1.12). Adjuvant endocrine therapy (aHR = 1.14; 95%CI = 1.10-1.19), aromatase inhibitors (aHR = 1.25; 95%CI = 1.18-1.32), and less so tamoxifen (aHR = 1.05; 95%CI = 0.99-1.11), were associated with elevated risk of T2D in women with BC vs cancer-free women. Among BC patients, chemotherapy (aHR = 1.10, 95%CI = 1.03-1.17) and radiation therapy (right-sided aHR = 1.18, 95%CI = 1.09-1.27 and left-sided aHR = 1.24, 95%CI = 1.15-1.33) were associated with increased T2D risk. BC was associated with excess risk of T2D, though of lower magnitude than previously reported. The excess risk was temporary and related to BC treatment but could also be influenced by obesity and heightened T2D diagnostic activity.


  • Open Access

    Correspondence to comment on: Impact of type 2 diabetes on complications after primary breast cancer surgery: Danish population-based cohort study

    by Kasper Kjærgaard, Jannik Wheler, Looket Dihge, Peer Christiansen, Signe Borgquist, Deirdre Cronin-Fenton

    Dear Editor

  • Open Access

    Impact of type 2 diabetes on complications after primary breast cancer surgery: Danish population-based cohort study

    by Kasper Kjærgaard, Jannik Wheler, Looket Dihge, Peer Christiansen, Signe Borgquist, Deirdre Cronin-Fenton

    Background: Knowledge is sparse on the impact of type 2 diabetes (T2D) on surgical outcomes after breast cancer surgery. This study investigated the association between T2D and risk of complications after primary breast cancer surgery, and evaluated the biological interaction between T2D and co-morbidities. Methods: Using the Danish Breast Cancer Group clinical database, a cohort of all Danish women diagnosed with early-stage breast cancer during 1996–2022 was created. All patients underwent mastectomy or breast-conserving surgery. Information on prevalent T2D was collected from Danish medical and prescription registries. Surgical complications were defined as hospital diagnoses for medical or surgical complications developing within 30 days after primary breast cancer surgery. The 30-day cumulative incidence proportion of complications was calculated, and Cox regression was used to estimate HRs. Interaction contrasts were computed to determine the additive interaction between T2D and co-morbidities on the incidence rate of complications. Results: Among 98 589 women with breast cancer, 6332 (6.4%) had T2D at breast cancer surgery. Overall, 1038 (16.4%) and 9861 (10.7%) women with and without T2D developed surgical complications, yielding cumulative incidence proportions of 16 (95% c.i. 15 to 17) and 11 (10 to 11)% respectively, and a HR of 1.43 (95% c.i. 1.34 to 1.53). The incidence rate of surgical complications explained by the interaction of T2D with moderate and severe co-morbidity was 21 and 42%, respectively. Conclusion: Women with breast cancer and T2D had a higher risk of complications after primary breast cancer surgery than those without T2D. A synergistic effect of T2D and co-morbidity on surgical complications can explain this association.


  • Open Access

    Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis

    by Nanna Jordt, Kasper Aalbæk Kjærgaard, Reimar W. Thomsen, Signe Borgquist, Deirdre Cronin-Fenton

    Purpose: Breast cancer and its treatments may increase the risk of type 2 diabetes (T2D). We conducted a systematic review and meta-analysis to investigate the association between breast cancer and the incidence of T2D overall, and according to breast cancer treatments. Methods: We searched PubMed, Embase and references of relevant papers for studies on breast cancer, breast cancer treatment, and subsequent T2D risk. Using random-effects models, we calculated effect estimates and associated 95% confidence intervals of the association between breast cancer, adjuvant breast cancer treatments (i.e., endocrine therapy (tamoxifen, aromatase inhibitors, and combined) and chemotherapy), and subsequent T2D. We used funnel plots to assess publication bias. Results: Among 15 eligible studies, 10 reported on T2D risk after breast cancer, chemotherapy, or endocrine therapy; five studies investigated more than one association. Compared with patients without breast cancer, those with breast cancer and those who received any endocrine therapy had elevated risk of incident T2D (EE = 1.23, 95% CI = 1.13–1.33 and EE = 1.23, 95% CI = 1.16–1.32, respectively). Among breast cancer patients only, the risk of T2D was higher for those who received tamoxifen compared with those who did not receive tamoxifen (EE = 1.28, 95% CI = 1.18–1.38). Due to few studies, analyses investigating T2D risk after treatment with aromatase inhibitors or chemotherapy were inconclusive. Conclusion: Our findings suggest an elevated risk of T2D in breast cancer survivors, particularly after tamoxifen therapy. Further research is needed to determine the impact of aromatase inhibitors, and chemotherapy on the incidence of T2D after breast cancer.


  • Top Cited Papers

    New Horizons: Epidemiology of Obesity, Diabetes Mellitus, and Cancer Prognosis

    by Sixten Harborg, Kasper A Kjærgaard, Reimar Wernich Thomsen, Signe Borgquist, Deirdre Cronin-Fenton, Cathrine F Hjorth

    The global prevalence of obesity and diabetes mellitus has increased in parallel with increasing cancer incidence, due to environmental and lifestyle factors and population aging. Metabolic diseases are associated with increased cancer risk, so a growing number of patients with cancer have coexistent obesity and/or diabetes mellitus. In this narrative review, we highlight recent evidence on the clinical impact of obesity and diabetes mellitus on the prognosis of prostate, breast, and colorectal cancer, and provide an overview of the underlying mechanisms. There is evidence that obesity is associated with increased risk of recurrence, and all-cause and cancer-specific mortality among adults with prostate, breast, and colorectal cancer. Diabetes mellitus is associated with increased all-cause and cancer-specific mortality for these 3 cancers, beyond any impact of obesity. Evidence also suggests increased risk of colorectal cancer recurrence in patients with diabetes mellitus. The underlying mechanisms are multifactorial and likely include hormonal imbalances and chronic inflammation that promote cancer cell growth. Obesity and diabetes mellitus are associated with increased risk of complications and side effects of cancer treatment. Associated comorbidities such as impaired kidney function, cardiovascular disease, and neuropathies may preclude the use of guideline cancer treatment and are competing causes of death. Cancer patients with metabolic diseases require a designated clinical program and a multidisciplinary approach involving oncologists, endocrinologists, surgeons, nutritionists, and physiotherapists, to ensure coordinated and optimized patient care.


  • Open Access

    Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study

    by Kasper Aalbæk Kjærgaard, Sixten Harborg, Henrik Kjærulf Jensen, Signe Borgquist

    Heterozygous familial hypercholesterolemia (HeFH) due to low-density lipoprotein receptor (LDLR) mutations predisposes patients to highly elevated levels of cholesterol, and patients are at increased risk of adverse cardiovascular events and other morbidities. Whether the LDLR mutation and high cholesterol levels affect the risk of cancer remains unknown. The purpose of the present study was to assess the long-term cancer risk in HeFH relatives. Study participants were identified by cascade screening during 1992–1994. A comparison cohort was matched 10:1 to the relatives from the Danish general population based on birth year, gender and address. All participants were followed until a cancer diagnosis, migration, death, or end of follow-up as of December 31, 2019. The primary endpoint was any incident cancer diagnosis. In total, we included 221 relatives with a median age of 37 years (interquartile range: 27–53 years). A total of 117 (53%) of the relatives carried a LDLR gene mutation. The crude hazard ratio of our primary endpoint did not reveal any differences in cancer incidence in mutation-carrying relatives compared with the general population cohort (1.18; 95% CI, 0.81–1.71). Nonmutation-carrying relatives however had a lower cancer incidence than the general population (0.45: 95% CI, 0.26–0.80). Thus, the risk among mutation-carrying HeFH relatives compared with nonmutation-carrying HeFH relatives was increased (HR: 2.39; 95% CI, 1.24–4.61). In Denmark, LDLR mutation-carrying HeFH relatives did not have a different cancer risk than the general population. In contrast, nonmutation-carrying relatives had a lower risk of cancer.